NEW YORK, Nov. 10 (GenomeWeb News) - Ciphergen Biosystems said today that it has discovered a biomarker pattern that correctly classified more than 96 percent of Alzheimer's disease patents and more than 94 percent of normal individuals using a four peak pattern of markers.
The company said the findings were presented at the Society for Neuroscience's annual meeting in New Orleans.
Ciphergen said that researchers analyzed cerebrospinal fluid from probable Alzheimer's diease pateints and age-matched normal individuals using the company's SELDI ProteinChip biomarker system and Expression Difference Mapping methodology.
Of the 39 candidate biomarkers found to be overexpressed among the Alzheimer's disease sufferers, a pattern of four was selected and used to correctly classify 29 of out 30 Alzheimer's disease patients and 33 of 35 normal individuals.
Ciphergen said that additional studies looking at more than 200 additional samples are underway to validate the markers' utility in diagnosing early-stage Alzheimer's disease and differentiating the condition from other dementias.